A106190 Stock Overview
High Tech Pharm Co., Ltd. researches and develops, manufactures, and sells injectable carbapenem-based antibiotics worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
High Tech Pharm Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩10,560.00 |
| 52 Week High | ₩11,186.67 |
| 52 Week Low | ₩7,880.00 |
| Beta | 0.90 |
| 1 Month Change | 5.60% |
| 3 Month Change | 25.27% |
| 1 Year Change | 17.51% |
| 3 Year Change | -12.00% |
| 5 Year Change | 16.04% |
| Change since IPO | 14.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| A106190 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -2.7% | 1.5% | 2.7% |
| 1Y | 17.5% | 9.1% | 5.8% |
Return vs Industry: A106190 exceeded the KR Pharmaceuticals industry which returned 9.1% over the past year.
Return vs Market: A106190 exceeded the KR Market which returned 5.8% over the past year.
Price Volatility
| A106190 volatility | |
|---|---|
| A106190 Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A106190's share price has been volatile over the past 3 months.
Volatility Over Time: A106190's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Jeong-Soo Kim | www.htpharm.com |
High Tech Pharm Co., Ltd. researches and develops, manufactures, and sells injectable carbapenem-based antibiotics worldwide. The company was incorporated in 1998 and is based in Chungju-si, South Korea.
High Tech Pharm Co., Ltd. Fundamentals Summary
| A106190 fundamental statistics | |
|---|---|
| Market cap | ₩112.29b |
| Earnings (TTM) | ₩8.08b |
| Revenue (TTM) | ₩76.77b |
13.9x
P/E Ratio1.5x
P/S RatioIs A106190 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A106190 income statement (TTM) | |
|---|---|
| Revenue | ₩76.77b |
| Cost of Revenue | ₩63.94b |
| Gross Profit | ₩12.83b |
| Other Expenses | ₩4.76b |
| Earnings | ₩8.08b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 759.56 |
| Gross Margin | 16.72% |
| Net Profit Margin | 10.52% |
| Debt/Equity Ratio | 15.4% |
How did A106190 perform over the long term?
See historical performance and comparison